MPN-MDS
US Focus Meeting 2026
📍 Downright Austin, A Renaissance Hotel, 701 E 11th St, Austin, TX 78701
🗓️ April 17 - 18, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the MPN-MDS Focus Meeting 2026, to be held at on April 17 - 18, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing MPN-MDS research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Cell Therapy & Bispecifics US Focus Meeting 2026:
Prithviraj Bose, MD
MD Anderson Cancer Center, Houston, TX
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
aimee.williams@md-education.com
Agenda & Faculty
April 17, 2026 | Day 1
08:40 AM
JAK inhibitors for the treatment of Myelofibrosis – a Remarkable Journey
Ruben Mesa, MD
Atrium Health Levine Cancer Institute, Charlotte, NC
Session I: MPN and MDS: Bench to Clinic
Moderated by:
TBD
TBD
TBD
09:30 AM
Inflammation and the MDS
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
09:30 AM
Inflammation and the MDS
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
09:50 AM
Hitting Mutant JAK2 Harder - Preclinical Considerations
TBD
KOL TBD
KOL TBD
10:10 AM
The Spectrum of Myeloid Neoplasm Abnormal Hematopoiesis
Michael R. Savona, MD
Vanderbilt University Medical Center, Nashville, TN
Session II: MPN and MDS Classifications and Risk Stratification
Moderated by:
TBD
TBD
TBD
11:10 AM
MDS and AML Classification Coming Together in 2026
TBD
KOL TBD
KOL TBD
11:30 AM
MPN Classification and Diagnosis
TBD
KOL TBD
KOL TBD
11:50 AM
Prognostic Modeling in Myelofibrosis
TBD
KOL TBD
KOL TBD
12:10 PM
State of the Art MDS Risk Stratification and Prognostication
TBD
KOL TBD
KOL TBD
Session III: PV, ET and CML
Moderated by:
TBD
TBD
TBD
02:25 PM
Interferons Come of Age in PV and ET
TBD
KOL TBD
KOL TBD
02:45 PM
Hepcidin Modulation in PV
Andrew Kuykendall, MD
Moffitt Cancer Center, Tampa, FL
03:05 PM
JAK Inhibition For PV and ET - Lessons Learned
Raajit K. Rampal, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
03:25 PM
How I Treat CML in 2026
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
Session IV: Myelofibrosis
Moderated by:
TBD
TBD
TBD
04:15 PM
New Therapeutic Targets in MPNs
Stephen T. Oh, MD
Washington University School of Medicine, St. Louis, MO
04:35 PM
Developing New Drugs for Anemia of Myelofibrosis - Advances and Challenges
Prithviraj Bose, MD
MD Anderson Cancer Center, Houston, TX
04:55 PM
Aiming for Disease Modification in Myelofibrosis – New Drugs, New Endpoints?
Pankit Vachhani, MD
UAB Medicine, Birmingham, AL
05:15 PM
Targeting Mutant JAK2 and Mutant CALR for Therapeutic Benefit in Myelofibrosis
Naveen Pemmaraju, MD
MD Anderson Cancer Center, Houston, TX
April 18, 2026 | Day 2
08:10 AM
Restoring the Genome Guardian: Targeting TP53 Myeloid Neoplasm
David Sallman, MD
Moffitt Cancer Center, Tampa, FL
Session V: Atypical MPN and MDS/MPN
Moderated by:
TBD
TBD
TBD
08:40 AM
Primer on Systemic Mastocytosis
TBD
KOL TBD
KOL TBD
09:00 AM
Primer on Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
JG
Jason Gotlib, MD
Stanford Medicine, CA
09:20 AM
CMML 2026 Updates
Eric Padron, MD
Moffitt Cancer Center, Tampa, FL
09:40 AM
MDS/MPN Other Than CMML and CNL 2026 Updates
Guillermo Montalban Bravo, MD
MD Anderson Cancer Center, Houston, TX
Session VI: Lower Risk MDS
Moderated by:
TBD
TBD
TBD
10:40 AM
EMA for Lower Risk MDS: Luspatercept and Elritrecept
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
11:00 AM
Telomerase Inhibition in LR-MDS
Yazan Madanat, MD
UT Southwestern Medical Center, Dallas, TX
11:20 AM
How I Sequence Therapies in LR-MDS
Mikkael A. Sekeres, MD
University of Miami Miller School of Medicine, Miami, FL
11:40 AM
Novel Agents in LR-MDS
Amy DeZern, MD
Johns Hopkins Medicine, Baltimore, MD
Session VII: Higher Risk MDS
Moderated by:
TBD
TBD
TBD
Debate: Verona Trial Ended the Dream in Higher Risk MDS to Move Beyond HMA
01:55 PM
No, Ventoclax is Still an Option
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX
02:15 PM
Yes, we Should Move Beyond Venetoclax
Uma Borate, MD
The Ohio State University, Comprehensive Cancer Center, Columbus, OH
02:35 PM
Novel Agents in Higher Risk MDS
Amer Zeidan, MD
Yale School of Medicine, New Haven, CT
02:35 PM
Taming the Bull Out of the Gate: Managing Secondary AML From MDS
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
Session VIII: AHSCT for MPN and MDS
Moderated by:
TBD
TBD
TBD
03:45 PM
Transplant for Myelofibrosis
Jeanne Palmer, MD
Mayo Clinic, Cleveland, OH
04:05 PM
Transplant for MDS
Bart Scott, MD
Fred Hutchinson Cancer Center, Seattle, WA
04:25 PM
Maintenance Strategies Post AHSCT for MDS and MPN
Alain Mina, MD
Northwestern Memorial Hospital, Chicago, IL
Rising stars in MDS and MPN
Moderated by:
Naveen Pemmaraju, MD
MD Anderson Cancer Center, Houston, TX
05:05 PM
TBD
TBD
KOL TBD
KOL TBD
05:25 PM
TBD
TBD
KOL TBD
KOL TBD
05:45 PM
TBD
TBD
KOL TBD
KOL TBD
06:05 PM
TBD
TBD
KOL TBD
KOL TBD
Aimee Williams
Project Manager
How long has Aimee Williams been in the business?
Aimee Williams has been with MD Education since 2022.
About Aimee Williams
I joined MD Education in 2022 as a Project Manager, leveraging my background in events management and passion for high-quality results. After earning a degree in Events Management, I gained hands-on experience managing projects while living in Nashville, TN. Driven and detail-oriented, I thrive in fast-paced environments, ensuring projects meet the highest standards. An avid traveler, I bring creativity and open-mindedness to problem-solving and client relationships.
